Antoine Papiernik net worth and biography

Antoine Papiernik Biography and Net Worth

Director of Shockwave Medical

Antoine Papiernik is the chairman and managing partner of Sofinnova Partners, a leading European venture capital firm in life sciences, specializing in healthcare and sustainability.

Papiernik has made initial investments and served as an active board member for numerous public companies, including Shockwave Medical, Actelion, ProQR, NovusPharma, Movetis, Mainstay, Pixium Vision and Stentys, Cotherix, CoreValve, Fovea, Ethical Oncology Science and Recor Medical.

Additionally, he has invested in and served on the boards of private companies such as Reflexion Medical, Pi-Cardia, Tissium, SafeHeal, Ablacare, Noema Therapeutics, Highlife and Rgenix. Papiernik has twice been recognized on the Forbes Midas List, one of just a few Europeans and life science investors to have been included on the prominent list.

Papiernik holds a B.S. from Institut Etudes Economiques Commerciales and an M.B.A. from the Wharton School of Business at the University of Pennsylvania.

What is Antoine Papiernik's net worth?: The estimated net worth of Antoine Papiernik is at least $4.10 million as of August 12th, 2022. Mr. Papiernik owns 12,251 shares of Shockwave Medical stock worth more than $4,101,022 as of March 30th. This net worth evaluation does not reflect any other investments that Mr. Papiernik may own. Learn More about Antoine Papiernik's net worth.
How do I contact Antoine Papiernik?: The corporate mailing address for Mr. Papiernik and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at investors@shockwavemedical.com. Learn More on Antoine Papiernik's contact information.
Has Antoine Papiernik been buying or selling shares of Shockwave Medical?: Antoine Papiernik has not been actively trading shares of Shockwave Medical over the course of the past ninety days. Most recently, Antoine Papiernik sold 50,000 shares of the business's stock in a transaction on Friday, August 12th. The shares were sold at an average price of $288.11, for a transaction totalling $14,405,500.00. Following the completion of the sale, the director now directly owns 12,251 shares of the company's stock, valued at $3,529,635.61. Learn More on Antoine Papiernik's trading history.
Who are Shockwave Medical's active insiders?: Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.

Antoine Papiernik Insider Trading History at Shockwave Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/12/2022	Sell	50,000	$288.11	$14,405,500.00	12,251
3/10/2022	Sell	60,000	$163.38	$9,802,800.00
5/28/2021	Sell	10,000	$177.55	$1,775,500.00	2,701
5/26/2021	Sell	77,357	$170.67	$13,202,519.19	2,701
3/1/2021	Sell	555,000	$120.00	$66,600,000.00	2,701
2/22/2021	Sell	350,000	$127.50	$44,625,000.00	2,701
11/23/2020	Sell	45,455	$99.76	$4,534,590.80	2,701
11/20/2020	Sell	23,400	$97.16	$2,273,544.00	2,701
11/18/2020	Sell	8,100	$97.01	$785,781.00	2,701
11/16/2020	Sell	68,514	$93.79	$6,425,928.06	2,701
11/13/2020	Sell	42,124	$92.97	$3,916,268.28	2,701
11/11/2020	Sell	27,400	$87.09	$2,386,266.00	2,701
11/9/2020	Sell	41,800	$80.44	$3,362,392.00	2,701
10/19/2020	Sell	9,500	$79.22	$752,590.00	2,701
10/16/2020	Sell	7,119	$79.01	$562,472.19	2,701
10/12/2020	Sell	455	$79.00	$35,945.00	2,701
10/9/2020	Sell	1,126	$79.00	$88,954.00	2,701
10/5/2020	Sell	24,587	$77.15	$1,896,887.05	2,701
10/1/2020	Sell	17,744	$75.32	$1,336,478.08	2,701
9/28/2020	Sell	17,347	$73.13	$1,268,586.11	2,701
9/18/2020	Sell	12,653	$73.19	$926,073.07	2,701
9/14/2020	Sell	78,528	$67.98	$5,338,333.44	2,701
8/27/2020	Sell	160,440	$60.43	$9,695,389.20
8/25/2020	Sell	60,657	$60.05	$3,642,452.85	2,701
8/20/2020	Sell	33,822	$60.01	$2,029,658.22	2,701
8/12/2020	Sell	1,300	$55.02	$71,526.00	2,701
8/5/2020	Sell	109,406	$50.71	$5,547,978.26	2,701
8/3/2020	Sell	85,549	$50.01	$4,278,305.49	2,701
6/10/2020	Sell	171,071	$43.94	$7,516,859.74
6/8/2020	Sell	59,879	$45.11	$2,701,141.69
6/5/2020	Sell	55,754	$45.04	$2,511,160.16
6/3/2020	Sell	7,996	$45.02	$359,979.92
6/1/2020	Sell	1,300	$45.00	$58,500.00
1/22/2020	Sell	54,920	$43.93	$2,412,635.60
1/17/2020	Sell	97,091	$44.64	$4,334,142.24
1/15/2020	Sell	58,333	$43.06	$2,511,818.98
9/4/2019	Sell	650,000	$34.35	$22,327,500.00

See Full Table

Antoine Papiernik Buying and Selling Activity at Shockwave Medical

Shockwave Medical Company Overview

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Today's Range

Now: $334.75

$334.75

50 Day Range

MA: $332.85

$328.87

$334.83

2 Week Range

Now: $334.75

$157.00

$334.90

Volume

N/A

Average Volume

968,088 shs

Market Capitalization

$12.57 billion

P/E Ratio

78.21

Dividend Yield